MA-WOLTERS-KLUWER-HEALTH
17.11.2022 20:01:35 CET | Business Wire | Press release
Wolters Kluwer Health and NEJM Group have entered into an exclusive partnership to ensure that more researchers and clinicians around the world can access the growing family of NEJM Group journals. Building on years of collaboration, this expanded partnership positions NEJM Group journals for sustained global growth through Wolters Kluwer’s Ovid® medical research platform. Publications currently included are the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst Innovations in Care Delivery, NEJM Journal Watch, the NEJM Archive, and future NEJM Group journals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005838/en/
Wolters Kluwer Health will serve as the exclusive digital distributor of subscriptions to the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst and NEJM Journal Watch (Graphic: Business Wire)
Unparalleled distribution critical to global reach
“The mission of NEJM Group is to advance medical knowledge from research to patient care, making the connections between developments in clinical science and clinical practice to improve healthcare quality and patient outcomes worldwide,” said David Sampson, Vice President of NEJM Group. “Wolters Kluwer’s worldwide sales and marketing presence creates additional opportunities to expand the reach of our content by delivering the NEJM Group portfolio of products to institutions globally.”
Through the partnership, institutional online subscribers to NEJM Group journals will be able to access their subscriber content both on NEJM Group sites and on the Ovid® medical research platform. Spanning over 150 publishers and more than 100 specialty areas, Ovid serves as the powerful, one-stop research software to help researchers, librarians, clinicians, and other healthcare professionals find timely and relevant medical information to make critical decisions to improve patient care, enhance ongoing research, and fuel new discoveries. With the addition of NEJM Group titles, Ovid users will be able to search and access the best research and information at the intersection of biomedical science and clinical practice, supporting improved patient care and clinical outcomes.
“The New England Journal of Medicine is one of the most highly respected and impactful medical periodicals in the world, drawing on a rich history, and cited more than any other journal,” said Vikram Savkar, Senior Vice President & General Manager, Medicine Segment, Health Learning, Research & Practice at Wolters Kluwer. “Leveraging Ovid’s market-leading search technology alongside Wolters Kluwer’s global sales and marketing reach will ensure more access to NEJM Group journals and archives around the world. Bringing together NEJM Group and Wolters Kluwer creates a global research powerhouse for clinicians seeking answers to care questions and researchers pursuing the next great discovery.”
The partnership builds on a strong foundation that has been fortified over many years of collaboration and a shared vision for the future of healthcare. Both NEJM Group and Wolters Kluwer maintain the highest standards for curation and peer review, and both support increased access to data and research globally. NEJM Group content around matters of public health importance, such as Covid-19, will continue to be available for free.
NEJM Group publications that will be distributed to institutions via Wolters Kluwer include:
- The New England Journal of Medicine, recognized as the world’s leading medical journal, delivering high-quality, peer-reviewed research and interactive clinical content to physicians, educators, researchers, and the global medical community.
- NEJM Evidence, which presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
- NEJM Catalyst Innovations in Care Delivery, a peer-reviewed journal focusing on the latest innovations, big ideas, and practical solutions for healthcare delivery transformation.
- NEJM Journal Watch, which helps clinicians efficiently understand medical developments to improve patient care and foster professional development.
As a result of this distribution agreement, Wolters Kluwer Health Learning, Research & Practice will account for NEJM Group digital subscription revenues and related costs. The agreement has a positive but immaterial impact on the consolidated earnings of the Wolters Kluwer group.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer Health provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
